Recursion Pharmaceuticals Inc. [RXRX] Insider Larson Tina Marriott sells 3,000 Shares – Insider Selling Alert


Recursion Pharmaceuticals Inc.’s filing revealed that its President and COO Larson Tina Marriott unloaded Company’s shares for reported $25968.0 on Aug 24. In the deal valued at $8.66 per share,3,000 shares were sold. As a result of this transaction, Larson Tina Marriott now holds 418,782 shares worth roughly $ 3.64 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Borgeson Blake sold 8,885 shares, generating $79,181 in total proceeds. Upon selling the shares at $8.91, the Director now owns 7,460,730 shares.

Before that, Secora Michael sold 25,000 shares. Recursion Pharmaceuticals Inc. shares valued at $222,518 were divested by the Chief Financial Officer at a price of $8.90 per share. As a result of the transaction, Secora Michael now holds 863,186 shares, worth roughly $7.51 million.

Morgan Stanley initiated its Recursion Pharmaceuticals Inc. [RXRX] rating to an Equal-weight in a research note published on Tuesday, May 22, 2023; the price target was $8. PT values the company’s stock at a premium of -8.75 to its Tuesday closing price.

Price Performance Review of RXRX

On Tuesday, Recursion Pharmaceuticals Inc. [NASDAQ:RXRX] saw its stock fall -4.61% to $8.70. On the same session, the stock had its day’s lowest price of $8.60, but rose to a high of $9.26. Over the last five days, the stock has gained 1.05%. Recursion Pharmaceuticals Inc. shares have risen nearly 12.84% since the year began. Nevertheless, the stocks have fallen -20.04% over the past one year. While a 52-week high of $16.75 was reached on 07/19/23, a 52-week low of $4.54 was recorded on 05/02/23. SMA at 50 days reached $10.36, while 200 days put it at $8.39. A total of 3.33 million shares were traded, compared to the trading of 2.76 million shares in the previous session.

Levels Of Support And Resistance For RXRX Stock

The 24-hour chart illustrates a support level at 8.45, which if violated will result in even more drops to 8.19. On the upside, there is a resistance level at 9.11. A further resistance level may holdings at 9.51. The Relative Strength Index (RSI) on the 14-day chart is 40.96, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 67.61%. Stochastics %K at 48.30% indicates the stock is a holding.

How much short interest is there in Recursion Pharmaceuticals Inc.?

A steep rise in short interest was recorded in Recursion Pharmaceuticals Inc. stocks on Aug 14, 2023, growing by 0.89 million shares to a total of 20.61 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 19.72 million shares. There was a rise of 4.32%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 15.48% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.69.

Recursion Pharmaceuticals Inc. [RXRX] – Who Are The Largest Shareholders?

In filings from Baillie Gifford & Co., it is revealed that the company now owns 25,097,630 shares, or roughly 13.59% of the outstanding RXRX shares. In other words, the investor’s shares have fallen by -37,900 from its previous 13-F filing of 25135530.0. Additionally, The Vanguard Group, Inc. increased 2.64% of its stake after which the total value it holdings stand at $155,777,629, while BlackRock Fund Advisors added 4.10% of its stake to hold $134.03 million in the firm. At present, ARK Investment Management LLC is holding 4,738,517 shares valued at $66.91 million. Fidelity Management & Research Co owned 4,557,935 shares of the company at the time of its most recent 13F filing, worth $64.36 million.

However, 8 analysts have rated RXRX stock as an Overweight in their predictions for 2023.


Please enter your comment!
Please enter your name here